CN106349225A - Tandospirone oxalate compound - Google Patents
Tandospirone oxalate compound Download PDFInfo
- Publication number
- CN106349225A CN106349225A CN201610715858.5A CN201610715858A CN106349225A CN 106349225 A CN106349225 A CN 106349225A CN 201610715858 A CN201610715858 A CN 201610715858A CN 106349225 A CN106349225 A CN 106349225A
- Authority
- CN
- China
- Prior art keywords
- oxalic acid
- tandospirone
- preparation
- solvent
- acid tandospirone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950000505 tandospirone Drugs 0.000 title claims abstract description 95
- -1 Tandospirone oxalate compound Chemical class 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000013078 crystal Substances 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 183
- 235000006408 oxalic acid Nutrition 0.000 claims description 69
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 67
- 239000002904 solvent Substances 0.000 claims description 30
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 12
- 150000002576 ketones Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000019901 Anxiety disease Diseases 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 241001310146 Ilex cornuta Species 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010038886 Retinal oedema Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 201000011195 retinal edema Diseases 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012905 visible particle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940122081 5 Hydroxytryptamine receptor agonist Drugs 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000013283 epinephrine uptake Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention provides a tandospirone oxalate compound. The invention also provides a preparation method of the tandospirone oxalate compound, a pharmaceutical composition containing the tandospirone oxalate compound and application. The tandospirone oxalate compound provided by the invention exists in a crystal form, and is stable in property and good in water solubility, and an effective solution path is provided for increasing the biological utilization degree and the safety of medicines; in addition, the tandospirone oxalate compound is simple in preparation technology, is high in yield and is suitable for industrial production.
Description
The application is the divisional application of Chinese 201410249410.x application for a patent for invention, and the applying date of this application is
On 06 06th, 2014, a kind of invention entitled oxalic acid tandospirone compound.
Technical field
The present invention relates to a kind of oxalic acid tandospirone compound is and in particular to the crystal form of this compound, and this change
The preparation method of solvate crystal, pharmaceutical composition and purposes.
Background technology
Tandospirone belongs to azaspiro ketone medicine, chemical entitled (3a α, 4 β, 7 β, 7a α)-hexahydro -2- [4 [4- (2- pyrimidines
Base) -1- (piperazinyl)-butyl] -4,7- methylene -1h- iso-indoles -1,3 (2h)-diketone, molecular structural formula is as follows:
Tandospirone is to be developed by SUMITOMO CHEMICAL Pharmaceutical Co., Ltd earliest, is approved to list in Japan in 1996.
It is a kind of 5-hydroxytryptamine receptor agonist, belongs to the 3rd generation antianxiety drugss, is mainly used in treating anxiety or other companion's anxiety states
Disease.In intracerebral, it can with integrated distribution emotion maincenter Hippocampus, in every, the cerebral limbic system such as interpeduncular nucleus, corpus amygdaloideum
And the 5-ht of seam gland core1aReceptor-selective ground combines, by exciting 5-ht1aAutoreceptor, adjusts and is projected to sea from rapheal nuclei
The 5-hydroxy tryptamine of horse, the 5-hydroxy tryptamine effect of suppression action suppression system, play angst resistance effect.Compared to original shape medicine azepine
Spiral shell ketone and with analog derivative buspirone, it has higher selectivity angst resistance effect, and this effect is close with diazepam, but
But little than diazepam in the toxic and side effects of the aspect such as nervimotion Sexual dysfunction and drug dependence.Special due to mechanism of action
Property, when tandospirone and its salt are used clinically for treating anxiety neurosis, have that drug safety is high, side reaction is few, no lax flesh
The advantages of meat and sedation, no dependence and drug withdrawal are given up phenomenon, no accumulate in vivo after prolonged application.
There are some researches show, tandospirone and its salt in addition to effect antianxity, controlling in other nervous system disease
Treat or auxiliary therapy aspect also has goodish application.Tandospirone and its salt have certain antidepressant effect, for
It is mixed with anxiety and depressed patient's curative effect is very notable, and vegetative nerve can be improved by anxiety and antidepressant effects
Symptom, such as irritable bowel syndrome, functional dyspepsia, postoperative nausea and vomiting etc..It still treats Central nervous system
Ataxic active drug, can be obviously improved the symptom of patient's cerebellar ataxia.For silly with neurasthenia, old age
The patient of slow-witted or schizophrenia, it can also effectively improve memory, and treatment increases rheological properties dysmnesia, significantly improves schizophrenia
The declarative memory of disease patient, logical memory and spoken paired-association etc..Swash additionally, there are some researches show as 5-hydroxytryptamine receptor
The tandospirone of dynamic agent and its salt also have the activity of intraocular pressure lowering, can be used for treatment due to endothelial cell proliferation, inflammation, blood vessel
The ocular disease that permeability improves or angiogenesis etc. cause, such as diabetic retinopathy, age-related macular degeneration,
Retinal edema, glaucoma etc..It can be seen that, tandospirone and its salt have very good clinical treatment advantage and wide city
Field prospect.
In clinical application, the drug molecule having nearly half is all to exist in a salt form and be administered.Electric on the contrary with band
The molecule of lotus or ion carry out into salt with medicine, can be effectively improved some undesirable physical chemistry of medicine or biopharmacy
Matter, for example, change the dissolubility of medicine, reduce hygroscopicity, improve stability, change fusing point, improve and grind performance, be easy to prepare
Purification, raising permeability etc..The poorly water-soluble of tandospirone, can be effectively improved its water solublity after becoming salt and physical chemistry is steady
Qualitative, improve bioavailability, therefore, tandospirone salt often has more than its original shape medicine tandospirone in medical application
Advantage, is conducive to having given play to the effect of medicine to greatest extent.The predominantly citric acid smooth degree spiral shell for example sold in the market
Ketone, the form of its usual tablets or capsule is widely used in the treatment of the relevant diseases such as anxiety neurosis, has comparative maturity
Clinical application research.And in the application of ophthalmic diseasess, Tandospirone Citrate can cause strong thorn because of its alkali to eye
Swash, so would generally consider during medication to select the hydrochloric acid tandospirone that zest is little, comfort level is high.
At present, the research for tandospirone salt is concentrated mainly on citrate and hydrochlorate.For example, us4507303,
The preparation method of Tandospirone Citrate, patent is reported in the documents such as us4818756, jp60087262, cn101362751a
Three kinds of crystal formations of Tandospirone Citrate are also disclosed that in cn10234442a.In addition, the preparation method of hydrochloric acid tandospirone is also
Disclosed in existing document, such as patent cn101880274a, us4507303, ep0082402 etc..With regard to presently disclosed document
In, yet there are no any preparation method with regard to other salifie form of tandospirone and the relevant report of crystal formation.
It is known that for medicine, the compound of different salifie form is likely to be of different crystal formations, same one-tenth
The compound of salt form there is likely to be polymorphic.And different crystal formations is possible to have different colors, fusing point, stablizes
Property, apparent solubility, rate of dissolution etc., these properties can directly influence the stability of pharmaceutical preparation, dissolubility, moisture absorption
Property, bioavailability etc., and thus lead to drug quality and the difference of clinical drug effect.Therefore, for the various salt of tandospirone
And its preparation of correlation crystal formation is significantly with research.
Content of the invention
It is an object of the invention to provide stable in properties, the good oxalic acid tandospirone compound of water solublity.
Present invention also offers preparation method, pharmaceutical composition and the purposes of oxalic acid tandospirone compound.
The invention provides a kind of preparation method of oxalic acid tandospirone, it includes following operation sequence:
A, take oxalic acid to be dissolved in solvent, make oxalic acid solution, take tandospirone, add solvent, after heating for dissolving, add grass
Acid solution, completely, reactant liquor is standby for question response；
B, reactant liquor naturally cool to room temperature, standing, take precipitation, are dried, obtain final product oxalic acid tandospirone.
Further, in step a, the mol ratio of tandospirone and oxalic acid is less than or equal to 1:1, and heating for dissolving temperature is 30～
100 DEG C, reaction temperature is 30～100 DEG C, and tandospirone is 1:1～30kg/l with the mass volume ratio of solvent, described solvent choosing
From water, acetonitrile, alcohol, ketones solvent, ether solvent, esters solvent any one or a combination thereof.
Wherein, tandospirone and the mol ratio of oxalic acid are preferably 1:(1～2).
Wherein, heating for dissolving temperature is preferably 30～90 DEG C, and reaction temperature is preferably 30～90 DEG C.
Wherein, tandospirone and the mass volume ratio of solvent are preferably 1:3～20kg/l.
Wherein, described solvent is preferably methanol, ethanol, isopropanol, acetone, water, oxolane, acetonitrile, ethyl acetate, second
Any one or a combination thereof of ether.
Further, in step b, time of repose is 1～16 hour, preferably 2～12 hours.
The invention provides a kind of oxalic acid tandospirone compound, this compound is characterised by that it is the shape with crystal formation
Formula exists, and when the compounds of this invention carries out x-ray powder diffraction using cu k α radiation source, the x-ray powder of described compound spreads out
Penetrate in figure, the 2 θ angles of diffraction are 13.0 ± 0.2,15.2 ± 0.2,16.4 ± 0.2,17.6 ± 0.2,18.4 ± 0.2,20.6 ± 0.2,
21.2 ± 0.2 degree have characteristic absorption peak.
Further, the x-ray powder diffraction in figure of described compound, the 2 θ angles of diffraction are also 5.4 ± 0.2,7.6 ± 0.2,
10.9 ± 0.2,12.1 ± 0.2,19.0 ± 0.2,19.3 ± 0.2,24.3 ± 0.2,30.1 ± 0.2 degree have characteristic absorption peak.
Preferably, the x-ray powder diffraction of described compound is as shown in Figure 1.
The structural formula of the compounds of this invention is:
Wherein, the fusing point of described compound is 161.5～163.0 DEG C.
Present invention also offers the preparation method of above-mentioned oxalic acid tandospirone compound, it includes following operation sequence:
A, take oxalic acid tandospirone, add solvent, after heating for dissolving, prepared oxalic acid tandospirone solution；
B, naturally cool to room temperature, standing, take precipitation, be dried, obtain final product oxalic acid tandospirone crystal formation.
Further, in step a, heating for dissolving temperature is 30～100 DEG C, the quality volume of oxalic acid tandospirone and solvent
For 1:1～30g/ml, described solvent is selected from any one or a combination thereof of ketones solvent, ether solvent to ratio.
Wherein, heating for dissolving temperature is preferably 30～60 DEG C.
Wherein, the preferred 1:1～25g/ml of mass volume ratio, more preferably 1:3～20g/ml of oxalic acid tandospirone and solvent.
Wherein, described solvent is preferably any one or a combination thereof of acetone, ether, more preferably acetone, acetone and ether
Mixed solution any one.
Further, in step b, time of repose is 1～16 hour, preferably 2～12 hours.The length of above-mentioned time of repose
Short, determine that whether completely this compound crystallize, has an impact to its yield, but do not interfere with the structure of crystal formation.
Present invention also offers above-mentioned oxalic acid tandospirone compound crystal form is in preparation treatment 5-hydroxy tryptamine or/and nor-
Purposes in the medicine of epinephrine reuptake relevant disease.
Wherein, described medicine is the medicine for the treatment of central nervous system disease and ocular disease, preferably treats anxiety
Disease, depression, Panic disorder, autism, infantile autism, insomnia, schizophrenia, increasing rheological properties dysmnesia, neurasthenia, old age
The medicine of the diseases such as dementia, glaucoma, diabetic retinopathy, age-related macular degeneration, retinal edema.
Further, purposes in preparing 5-hydroxy tryptamine regulator for the above-mentioned oxalic acid tandospirone compound crystal form.
Wherein, described 5-hydroxy tryptamine regulator is the medicine for the treatment of anxiety neurosis, depression or insomnia.
Present invention also offers a kind of pharmaceutical composition, it is with above-mentioned oxalic acid tandospirone compound crystal form as activity
Composition, adds the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
Pharmaceutically acceptable adjuvant of the present invention or complementary composition, be known in the art for preparing above-mentioned system
The usual excipients of agent or adjuvant.The excipient that oral formulations or external preparation are commonly used or adjuvant include but are not limited to filler
(diluent), lubricant (fluidizer or antitack agent), dispersant, wetting agent, binding agent, regulator, solubilizing agent, antioxidant,
Antibacterial, emulsifying agent, disintegrating agent etc..Binding agent such as syrup, arabic gum, gelatin, starch slurry, polyvidone, cellulose family derive
Thing etc.；Filler such as Lactose, dextrin, starch and its derivant, cellulose derivative, inorganic calcium salt, Mannitol, agar powder
Etc.；Lubricant such as micropowder silica gel, stearic acid and its esters, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols etc.；Disintegrating agent
As starch and its derivant, Crospovidone, cellulose derivative etc.；Wetting agent such as water, alcohols or other organic solvents
Etc..Described injection commonly use excipient or adjuvant include but are not limited to: antioxidant for example sodium sulfite, sodium sulfite,
Sodium pyrosulfite, sodium thiosulfate etc.；Antibacterial such as phenol, benzyl alcohol, hydroxypropyl methyl ester, chlorobutanol etc.；Regulator
Example hydrochloric acid, citric acid, potassium hydroxide (sodium), buffer agent etc.；Emulsifying agent such as polyoxyethylene sorbitan monoleate, lecithin, fabaceous lecithin etc.；Increase
Solvent such as Tween 80, bile, glycerol etc..Additionally, also can by active component and pharmaceutically acceptable slow controlled release carrier, according to
The preparation method of sustained-release preparation known in the art makes sustained-release preparation.
The dosage form of compositionss of the present invention, can be liquid preparation, gaseous formulation, solid preparation and semi-solid system
Agent, preferred fragrance water preparation, solution, injection, mixture, lotion, liniment, aerosol, spray, powder, pill, tablet, film
The common formulations such as agent, ointment, suppository, paste.
The oxalic acid tandospirone compound that the present invention provides, has filled up the blank of prior art；With existing product citric acid
Tandospirone is compared, the oxalic acid tandospirone compound that the present invention provides, its stable in properties, and water solublity is good, for improving medicine
Bioavailability and safety provide a kind of effective solution route；In addition, the preparation process is simple of the compounds of this invention,
High income is it is adaptable to industrialized production.
Brief description
The x-ray powder diffraction spectrum of Fig. 1 embodiment of the present invention 3 gained oxalic acid tandospirone crystal formation.
The x-ray powder diffraction spectrum of gained oxalic acid tandospirone crystal formation under the conditions of Fig. 2 embodiment of the present invention 4 numbering 4.
Specific embodiment
In the present invention, raw materials used tandospirone is to obtain with reference to existing preparation technology synthesis, for example
The method of report in the patent documentations such as cn101362751a, us5521313.Certainly, in addition to being synthesized by existing method, this
Tandospirone used by invention can also be obtained by buying commercial goods.
The preparation of embodiment 1 oxalic acid tandospirone
Weigh 0.66kg oxalic acid and be dissolved in 2l isopropanol, be configured to the aqueous isopropanol of oxalic acid.Weigh 2kg tandospirone, plus
Enter 10l isopropanol, be heated to 90 DEG C, after molten clear after, add oxalic acid aqueous isopropanol configure, continue stirring extremely reaction
Completely, stop heating, be naturally cooled to room temperature and place 2 hours, sucking filtration, washing, it is dried, obtains final product 2.42kg oxalic acid tandospirone, receive
Rate is 98.0%, and mass spectrum shows its esi m/z:383 (m+).
The preparation of embodiment 2 oxalic acid tandospirone
Method according to embodiment 1 prepares oxalic acid tandospirone, and, referring to table 1, the inventory of tandospirone is equal for actual conditions
For 2kg.The results of structural analysis no significant difference of the results of structural analysis of products obtained therefrom and embodiment 1 under the conditions of each.
The preparation of table 1 oxalic acid tandospirone
Note: in table, mixed solvent ratio is volume ratio.
The preparation of embodiment 3 oxalic acid tandospirone compound crystal form
Weigh 200g oxalic acid tandospirone, add 2000ml acetone and 2000ml ether, be heated to 35 DEG C, to be dissolved
Completely, stop heating after continuing stirring 30min, be naturally cooled to room temperature and place 4 hours, sucking filtration, washing, it is dried, obtain final product 195g white
Color powder oxalic acid tandospirone crystal formation, yield is 97.5%.Mass spectrum shows its esi m/z:383 (m+), record its fusing point
For 161.5 DEG C～163.0 DEG C.
Using dx-2700 type x- ray powder diffractometer, sample crystalline phase is analyzed, cu k α radiates, and records oxalic acid smooth
The x-ray powder diffraction spectrum of degree spiral shell ketone crystal formation is shown in Fig. 1, main associated diffraction data be shown in Table 2 (2 θ measurement error are ±
0.2).
The x-ray powder diffraction data of table 2 oxalic acid tandospirone crystal formation
The preparation of embodiment 4 oxalic acid tandospirone compound crystal form
Prepare oxalic acid tandospirone crystal formation according to method described in embodiment 3, actual conditions referring to table 3, the smooth degree of oxalic acid
The inventory of spiral shell ketone is 200g.The results of structural analysis of products obtained therefrom and x-ray powder diffraction spectrum and enforcement under the conditions of each
Example 3 no significant difference, determines that it is oxalic acid tandospirone crystal formation, and partly Fig. 2 is shown in by representative x-ray diffraction collection of illustrative plates.
The preparation of table 3 oxalic acid tandospirone crystal formation
Note: in table, mixed solvent ratio is volume ratio.
The capsule of embodiment 5 present invention
After the oxalic acid tandospirone crystal formation of amount to be prepared and starch are mixed by equal increments method, then with microcrystalline cellulose
Element mixes, and pelletizes, encapsulated obtains final product.
Below by way of test example, beneficial effects of the present invention are described.
Test example 1 solubility test
Test group: the oxalic acid tandospirone crystal formation that the embodiment of the present invention 3 prepares；
Matched group: the Chinese holly preparing with reference to method disclosed in existing document (cn101880274a, cn101362751a)
Rafter acid tandospirone.
Weigh test sample 2g, be placed in 25 ± 2 DEG C of 20ml water, every strength shaking in 1 minute 10 seconds, observe 3 minutes
Interior dissolving situation.As nothing visually visible particles of solute, that is, it is considered as being completely dissolved；If there being visually visible particles of solute,
Add the water (i.e. 10ml water) of 5 times of volumes of test sample weight, repeat aforementioned operation, until being completely dissolved.Record total water consumption
With the time, the results are shown in Table 4.
Table 4 dissolubility comparative study
Dissolubility test result in table 4 shows, the oxalic acid tandospirone crystal formation that the present invention prepares is in water
Dissolution time is substantially short than the dissolution time of existing product Tandospirone Citrate, and dissolubility is more excellent.Under normal circumstances, good water
Dissolubility is not only curative effect of medication and safety provides strong guarantee, but also can reduce the thorn producing during clinical application
Swash, improve the compliance of patient, this advantage is especially prominent in the application of injection and ophthalmic preparations.
Test example 2 stabilizing effect is tested
Test group: the oxalic acid tandospirone crystal formation that the embodiment of the present invention 3 prepares；
Matched group: the Chinese holly preparing with reference to method disclosed in existing document (cn101880274a, cn101362751a)
Rafter acid tandospirone.
Study on the stability condition includes: (1) thermal degradation: takes test sample about 200mg, is placed in 60 DEG C of drying baker and places；(2)
Light degradation: take test sample about 200mg, be placed in the environment that illuminance is 4500 ± 5001x and place；(3) high humidity degraded: take for examination
Product about 200mg, is placed in and is placed with kno3In the exsiccator of saturated solution, room temperature is placed.Stability test the results are shown in Table 5.
Table 5 stability test result
Shown by the result of the test in table 5, the oxalic acid tandospirone crystal formation of present invention preparation, in high temperature, high humidity, illumination
Under conditions of purity have no significant change.As can be seen here, not only purity is high for the oxalic acid tandospirone crystal that the present invention provides, and
Stable and controllable for quality, the manufacture of suitable pharmaceutical preparation and long term storage.
In sum, compared with existing product Tandospirone Citrate, the oxalic acid tandospirone crystal formation that the present invention provides,
Its stable in properties, water solublity is good, and bioavailability and safety for improving medicine provide a kind of effective solution route；
In addition, the preparation process is simple of the compounds of this invention, high income is it is adaptable to industrialized production.
Claims (10)
1. a kind of oxalic acid tandospirone compound it is characterised in that: this compound is presented in crystal formation, described chemical combination
The x-ray powder diffraction in figure of thing, the 2 θ angles of diffraction are 13.0 ± 0.2,15.2 ± 0.2,16.4 ± 0.2,17.6 ± 0.2,18.4
± 0.2,20.6 ± 0.2,21.2 ± 0.2 degree have characteristic absorption peak；Be preferably the 2 θ angles of diffraction also 5.4 ± 0.2,7.6 ± 0.2,
10.9 ± 0.2,12.1 ± 0.2,19.0 ± 0.2,19.3 ± 0.2,24.3 ± 0.2,30.1 ± 0.2 degree have characteristic absorption peak；More
Preferably there is x-ray powder diagram substantially as shown in Figure 1.
2. according to claim 1 oxalic acid tandospirone compound it is characterised in that: the preparation method of this compound include as
Lower operation sequence:
A, take oxalic acid tandospirone, add solvent, after heating for dissolving, prepared oxalic acid tandospirone solution；
B, naturally cool to room temperature, standing, take precipitation, be dried, obtain final product oxalic acid tandospirone crystal formation.
Wherein, described solvent is selected from any one or a combination thereof of ketones solvent, ether solvent, preferably acetone, ether arbitrary
Plant or a combination thereof.
3. oxalic acid tandospirone compound according to claim 2 preparation method it is characterised in that: in step a, oxalic acid
Tandospirone is 1:1～30g/ml with the mass volume ratio of solvent, preferably 1:1～25g/ml, more preferably 1:3～20g/ml.
4. the oxalic acid tandospirone compound according to claim 2 or claim 3 preparation method it is characterised in that:
In step a, heating for dissolving temperature is 30～100 DEG C, preferably 30～60 DEG C.
5. the oxalic acid tandospirone compound according to any one in claim 2-4 preparation method it is characterised in that:
The preparation method of step a mesoxalic acid tandospirone, including following operation sequence:
A, take oxalic acid to be dissolved in solvent, make oxalic acid solution, take tandospirone, add solvent, after heating for dissolving, add oxalic acid molten
Liquid, completely, reactant liquor is standby for question response；
B, reactant liquor naturally cool to room temperature, standing, take precipitation, are dried, obtain final product oxalic acid tandospirone；
Wherein, described solvent is selected from any one or a combination thereof of water, acetonitrile, alcohol, ketones solvent, ether solvent, esters solvent；Excellent
Elect any one or a combination thereof of methanol, ethanol, isopropanol, acetone, water, oxolane, acetonitrile, ethyl acetate, ether as.
6. oxalic acid tandospirone compound according to claim 5 preparation method it is characterised in that: in step a, smooth degree
Spiral shell ketone is less than or equal to 1:1, preferably 1:(1～2 with the mol ratio of oxalic acid).
7. the oxalic acid tandospirone compound according to claim 5 or claim 6 preparation method it is characterised in that:
In step a, tandospirone is 1:1～30kg/l, preferably 1:3～20kg/l with the mass volume ratio of solvent.
8. the oxalic acid tandospirone compound according to claim 5-7 any one preparation method it is characterised in that: step
In rapid a, heating for dissolving temperature is 30～100 DEG C, preferably 30～90 DEG C；Further, in step a, reaction temperature is 30
～100 DEG C, preferably 30～90 DEG C.
9. a kind of pharmaceutical composition it is characterised in that: it is as work containing oxalic acid tandospirone compound described in claim 1
Property composition, adds the pharmaceutical preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
10. oxalic acid tandospirone compound described in claim 1 is in preparation treatment with 5-hydroxy tryptamine or/and norepinephrine again
Purposes in the medicine of picked-up relevant disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610715858.5A CN106349225A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610715858.5A CN106349225A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
| CN201410249410.XA CN105175398A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410249410.XA Division CN105175398A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106349225A true CN106349225A (en) | 2017-01-25 |
Family
ID=54897913
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410249410.XA Pending CN105175398A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
| CN201610720007.XA Pending CN106467520A (en) | 2014-06-06 | 2014-06-06 | A kind of oxalic acid tandospirone compound |
| CN201610715858.5A Pending CN106349225A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
| CN201610720948.3A Pending CN106349227A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410249410.XA Pending CN105175398A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
| CN201610720007.XA Pending CN106467520A (en) | 2014-06-06 | 2014-06-06 | A kind of oxalic acid tandospirone compound |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610720948.3A Pending CN106349227A (en) | 2014-06-06 | 2014-06-06 | Tandospirone oxalate compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN105175398A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109745323A (en) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | Azapirone compound improves the active purposes of parasympathetic nerve |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| US4598078A (en) * | 1982-10-21 | 1986-07-01 | Sumitomo Chemical Company, Limited | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives |
| CN103641817A (en) * | 2011-08-04 | 2014-03-19 | 成都科瑞德医药投资有限责任公司 | Novel crystal form of tandospirone citrate, preparation method and applications |
| CN103755687A (en) * | 2013-12-25 | 2014-04-30 | 成都科瑞德医药投资有限责任公司 | Hydrochloric tandospirone crystal form I and preparation method of crystal form I |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103641818B (en) * | 2011-08-04 | 2015-08-12 | 四川科瑞德制药有限公司 | A kind of SM-3997 compound and its production and use |
| CN103664905B (en) * | 2013-12-25 | 2015-10-14 | 四川科瑞德制药有限公司 | Hydrochloric acid Tandospirone crystal form II and preparation method thereof |
-
2014
- 2014-06-06 CN CN201410249410.XA patent/CN105175398A/en active Pending
- 2014-06-06 CN CN201610720007.XA patent/CN106467520A/en active Pending
- 2014-06-06 CN CN201610715858.5A patent/CN106349225A/en active Pending
- 2014-06-06 CN CN201610720948.3A patent/CN106349227A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| US4598078A (en) * | 1982-10-21 | 1986-07-01 | Sumitomo Chemical Company, Limited | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives |
| CN103641817A (en) * | 2011-08-04 | 2014-03-19 | 成都科瑞德医药投资有限责任公司 | Novel crystal form of tandospirone citrate, preparation method and applications |
| CN103755687A (en) * | 2013-12-25 | 2014-04-30 | 成都科瑞德医药投资有限责任公司 | Hydrochloric tandospirone crystal form I and preparation method of crystal form I |
Non-Patent Citations (2)
| Title |
|---|
| 四川医学院主编: "《药物化学》", 31 January 1981, 中国医药科技出版社 * |
| 本书编委会编: "《新时期食品药品规范化管理全书》", 31 January 2007, 经济日报出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106349227A (en) | 2017-01-25 |
| CN106467520A (en) | 2017-03-01 |
| CN105175398A (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104736526B (en) | Fertile for western spit of fland salt and crystal thereof, their preparation method, pharmaceutical composition and purposes | |
| RU2347774C2 (en) | Crystalline substance for peroral solid medicinal preparation and peroral solid medicinal preparation for treating dysuria, containing this substance | |
| KR101576695B1 (en) | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | |
| EA012594B1 (en) | Amino acid salts of rosiglitazone | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| DE69607904T2 (en) | Potentiation of serotonin drug response | |
| JP2017081957A (en) | Compound | |
| CN103877088A (en) | Melitracen pharmaceutical composition with high security | |
| JP7007300B2 (en) | New crystalline form of dapagliflozin and its manufacturing method and application | |
| CN105566314B (en) | A kind of Tizanidine compound | |
| KR20120137403A (en) | Aildenafil citrate crystal form o, preparation method and use thereof | |
| CN105001195B (en) | Novel crystal forms of R (+) lipoic acid L lysine salts and preparation method thereof | |
| CN103755687A (en) | Hydrochloric tandospirone crystal form I and preparation method of crystal form I | |
| CN106349225A (en) | Tandospirone oxalate compound | |
| CN106749196B (en) | 5-hydroxytryptamine receptor agonist | |
| CN106349226A (en) | L-tartaric acid tandospirone compound | |
| CN105985327A (en) | Tandospirone citrate compound | |
| CN116018330A (en) | Crystalline form of deuterium-enriched pioglitazone | |
| CN106397411B (en) | 5-hydroxytryptamine receptor agonist and preparation method and application thereof | |
| CN106397413B (en) | 5-hydroxytryptamine receptor agonist and preparation method and application thereof | |
| CN106397410B (en) | 5-hydroxytryptamine receptor agonist and preparation method and application thereof | |
| CN106905302B (en) | Azaspiroanone compound and preparation method thereof | |
| CN106810563B (en) | Furankasane diterpene derivatives and pharmaceutical compositions thereof and their application in pharmacy | |
| CN113831252A (en) | Venlafaxine caffeate and preparation method, composition and application thereof | |
| CN106397412A (en) | 5-hydroxytryptamine receptor agonists, a preparing method thereof and uses of the receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |